Close Menu

Grail

Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.

The financing round will support Grail's ongoing development and validation of early cancer detection products.

The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.

The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.

In a training subset of the larger cohort, the company was able to develop classifiers that detected many cancers while minimizing false positives.

The firm plans to launch a nasopharyngeal carcinoma test in Asia this year and is developing breast cancer tests to supplement mammograms.

Technologies gained one of their first solid footholds in the clinical care of cancer patients with adoption into the treatment paradigm of lung cancer, while researchers turned their eyes to proving utility in other niches.

Cirina will operate as a subsidiary of Grail and the combined entity will collaborate with Dennis Lo's lab at the Chinese University of Hong Kong. 

Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.

Grail plans to raise a total of more than $1 billion before the end of the first quarter.

Pages